Medicare and Medicaid would cover weight-loss drugs like Wegovy and Ozempic under a new rule proposed by President Joe Biden on Tuesday, increasing access to the widely popular medications to millions of adults with obesity in the U.S., though the plan would likely face opposition under President-elect Donald Trump's second administration.

Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $ 35 billion proposal from the Biden administration is blessed by President-elect Donald Trump.

The Biden administration proposed a rule for Medicare and Medicaid to cover the costs of weight-loss drugs for millions of Americans with obesity.

The diabetes drug, Ozempic, has been in the headlines, causing quite a stir. Senior writer for Drugwatch.com, Terry Turner, joined LiveNow to discuss how some people are ending up in the hospital, for misusing Ozempic as a weight loss drug.

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce risks with obesity.

The Biden administration on Tuesday proposed requiring Medicare and Medicaid to cover anti-obesity drugs. Why it matters: The rule would expand access to the medications for millions of Americans struggling with obesity,

Millions of Americans could soon have access to weight-loss medications that some have called "miracle drugs."

President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Wegovy, Ozempic, Zepbound and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.